Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein tyrosine phosphatase type IVA 3 (PTP4A3 (also commonly known as PRL-3))
- Target
- PTP4A3 (also commonly known as PRL-3)
- Molecular classification
- Enzyme, Protein tyrosine phosphatase (non-receptor type), Dual-specificity phosphatase, Prenylated membrane-associated phosphatase
01
Overview
Protein tyrosine phosphatase type IVA 3 (PTP4A3/PRL-3) is a prenylated, dual-specificity, non-receptor protein tyrosine phosphatase that regulates key signaling pathways involved in cell proliferation and migration. It is highly expressed in various cancers, notably metastatic colorectal cancers, T-cell acute lymphoblastic leukemia, and uveal melanoma, where it contributes to tumor progression, invasion, and angiogenesis. Mechanistically, PTP4A3/PRL-3 modulates Src signaling and is involved in the regulation of matrix metalloproteinases (e.g., MMP14), facilitating tumor cell migration and invasion. PTP4A3 is considered a promising therapeutic target, and ongoing research focuses on the development of inhibitory compounds and their application in personalized cancer therapy
- Other names
- Phosphatase of regenerating liver 3 (PRL-3)PRL3PRL-3PRL-R
02
Mechanism of action
Inhibitors block phosphatase activity, leading to reduced cell migration, invasion, tumor metastasis, and decreased VEGF-mediated angiogenesis
03
Biological functions
Cell signalingCell migrationCell proliferationRegulation of angiogenesisTumor progression and metastasis
04
Disease associations
Cancer (including colon, gastrointestinal, T-cell acute lymphoblastic leukemia, and uveal melanoma)MetastasisAngiogenesis-related pathologies
05
Safety considerations
Targeting phosphatases can affect normal cell signaling; off-target effects may impact vascular function and immune cells due to widespread expression of PTP4A3. Limited clinical data available on toxicities of specific inhibitors
06
Interacting drugs
Small molecule inhibitors (specific FDA-approved drugs are being explored; names not standardized or published as clinical therapies yet)
07
Biomarkers
PRL-3 (PTP4A3) expression is a biomarker for metastatic potential in cancers, especially gastrointestinal tumors and T-cell ALL
Beyond the preview
Go deeper on Protein tyrosine phosphatase type IVA 3 (PTP4A3 (also commonly known as PRL-3)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein tyrosine phosphatase type IVA 3 (PTP4A3 (also commonly known as PRL-3)).